https://www.cancernetwork.com/view/olaparib-may-prolong-pfs-regardless-of-mutation-location-in-ovarian-cancer
0
0
1/31/23 at 1:03pm
Organization
Cancernetwork.com
Author
Nicholas Wrigley
44 words
0
Comments
Maintenance olaparib plus bevacizumab may improve survival in patients with high-grade ovarian cancer regardless of BRCA mutation location, according to a subgroup analysis of the PAOLA-1/ENGOT-ov25 trial.
You are the first to view
Create an account
or login to join the discussion